心房颤动治疗新方向——延迟钠电流阻滞剂雷诺嗪  

Late Sodium Current Inhibitor Ranolazine——A Novel Anti-atrial Fibrillation Drug

作　　者：贺鹏康[1] 周菁[1] 

机构地区：[1]北京大学第一医院心内科,北京100034

出　　处：《心血管病学进展》2015年第1期1-3,共3页Advances in Cardiovascular Diseases

摘　　要：延迟钠电流阻滞剂雷诺嗪最初作为抗心绞痛药物使用,其抗心律失常作用逐渐显露。目前临床研究提示雷诺嗪存在抑制心房颤动的作用,而基础研究在一定程度上解释了雷诺嗪抗心房颤动的作用。雷诺嗪展示出的有效性及安全性使其成为有前景的新型抗心律失常药物。Late sodium current inhibitor ranolazine was prescribed as anti-ischemia drug in the first place. However,more and more clinical researches revealed its capability in anti-arrhythmias especially suppressing atrial fibrillation. Furthermore,other studies might partially explained the mechanism in reducing atrial fibrillation. Both effectiveness and safety could guarantee ranolazine a promising future as a novel anti-arrhythmias drug.

关 键 词：雷诺嗪 心房颤动 延迟钠电流阻滞剂 新型抗心律失常药物 

分 类 号：R541.75[医药卫生—心血管疾病]